[1]
|
WHO (2022) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
|
[2]
|
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C. and Napo, R.D. (2022) Features, Evaluation, and Treatment of Coronavirus (COVID-19). 1st Edition, StatPearls Publishing, Treasure Island.
|
[3]
|
Alhazzani, W., Moller, M.H., Arabi, Y.M., Loeb, M., Gong, M.N., Fan, E., Oczkowski, S., Levy, M.M., Derde, L., Dzierba, A., Du, B., Aboodi, M., Wunsch, H., Cecconi, M., Koh, Y., Chertow, D.S., Maitland, K., Alshamsi, F., Belley-Cote, E., Greco, M., Laundy, M., Morgan, J.S., Kesecioglu, J., McGeer, A., Mermel, L., Mammen, M.J., Alexander, P.E., Arrington, A., Centofanti, J., Citerio, G., Baw, B., Memish, Z.A., Hammond, N., Hayden, F.G., Evans, L. and Rhodes, A. (2020) Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 46, 854-887. https://doi.org/10.1007/s00134-020-06022-5
|
[4]
|
Mahase, E. (2021) COVID-19: Pfizer’s Paxlovid Is 89% Effective in Patients at Risk of Serious Illness, Company Reports. British Medical Journal, 375, n2713. https://doi.org/10.1136/bmj.n2713
|
[5]
|
Marconi, V.C., Ramanan, A.V., de Bono, S., Kartman, C.E., Krishnan, V., Liao, R., Piruzeli, M.L.B., Goldman, J.D., Alatorre-Alexander, J., Pellegrini, R.D., Estrada, V., Som, M., Cardoso, A., Chakladar, S., Crowe, B., Reis, P., Zhang, X., Adams, D.H. and Ely, E.W. (2021) Efficacy and Safety of Baricitinib for the Treatment of Hospitalised Adults with COVID-19 (COV-BARRIER): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial. The Lancet Respiratory Medicine, 9, 1407-1418. https://doi.org/10.1016/S2213-2600(21)00331-3
|
[6]
|
Cingolani, A., Tummolo, A.M., Montemurro, G., Gremese, E., Larosa, L., Cipriani, M.C., Pasciuto, G., Liperoti, R., Murri, R., Pirronti, T., Cauda, R. and Fantoni, M. (2020) Baricitinib as Rescue Therapy in a Patient with COVID-19 with No Complete Response to Sarilumab. Infection, 48, 767-771. https://doi.org/10.1007/s15010-020-01476-7
|
[7]
|
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Casal, M.C., Moya, J., Falci, D.R., Sarkis, E., Solis, J., Zheng, H.Z., Scott, N., Cathcart, A.L., Hebner, C.M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P.S., Free, A., Brinson, C., Aldinger, M. and Shapiro, A.E. (2021) Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New England Journal of Medicine, 385, 1941-1950. https://doi.org/10.1056/NEJMoa2107934
|
[8]
|
Cao, Y., Wei, J., Zou, L., Jiang, T.B., Wang, G.X., Chen, L.T., Huang, L., Meng, F.K., Huang, L.F., Wang, N., Zhou, X.X., Luo, H., Mao, Z.K., Chen, X., Xie, J.G., Liu, J., Cheng, H., Zhao, J.P., Huang, G., Wang, W. and Zhou, J.F. (2020) Ruxolitinib in Treatment of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter, Single-Blind, Randomized Controlled Trial. Journal of Allergy and Clinical Immunology, 146, 137-146.E3. https://doi.org/10.1016/j.jaci.2020.05.019
|
[9]
|
Guimaraes, P.O., Quirk, D., Furtado, R.H., Maia, L.N., Saraiva, J.F., Antunes, M.O., Kalil, R., Junior, V.M., Soeiro, A.M., Tognon, A.P., Veiga, V.C., Martins, P.A., Moia, D.D.F., Sampaio, B.S., Assis, S.R.L., Soares, R.V.P., Piano, L.P.A., Castilho, K., Momesso, R., Monfardini, F., Guimaraes, H.P., de Leon, D.P., Dulcine, M., Pinheiro, M.R.T., Gunay, L.M., Deuring, J.J., Rizzo, L.V., Koncz, T., Berwanger, O. and Investigators, S.C.T. (2021) Tofacitinib in Patients Hospitalized with COVID-19 Pneumonia. New England Journal of Medicine, 385, 406-415. https://doi.org/10.1056/NEJMoa2101643
|
[10]
|
Murdock, J. (2022) The Latest Updates on COVID-19 Treatments and Medications in the Pipeline. Goodrx Health. https://www.goodrx.com/conditions/covid-19/coronavirus-treatments-on-the-way
|
[11]
|
Wen, W., Chen, C., Tang, J.K., Wang, C.Y., Zhou, M.Y., Cheng, Y.R., Zhou, X., Wu, Q., Zhang, X.W., Feng, Z.H., Wang, M.W. and Mao, Q. (2022) Efficacy and Safety of Three New Oral Antiviral Treatment (Molnupiravir, Fluvoxamine and Paxlovid) for COVID-19: A Meta-Analysis. Annals of Medicine, 54, 516-523. https://doi.org/10.1080/07853890.2022.2034936
|
[12]
|
Singh, A.K., Singh, A., Singh, R. and Misra, A. (2021) Molnupiravir in COVID-19: A Systematic Review of Literature. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, Article ID: 102329. https://doi.org/10.1016/j.dsx.2021.102329
|
[13]
|
Lestari, M.L.A.D. and Indrayanto, G. (2014) Curcumin. Profiles of Drug Substances, Excipients and Related Methodology, 39, 113-204. https://doi.org/10.1016/B978-0-12-800173-8.00003-9
|
[14]
|
Mahady, G.B., Pendland, S.L., Yun, G. and Lu, Z. (2002) Turmeric (Curcuma longa) and Curcumin Inhibit the Growth of Helicobacter pylori, a Group 1 Carcinogen. Anticancer Research, 22, 4179-4181.
|
[15]
|
Anand, P., Kunnumakkara, A.B., Newman, R.A. and Aggarwal, B.B. (2007) Bioavailability of Curcumin: Problems and Promises. Molecular Pharmaceutics, 4, 807-818. https://doi.org/10.1021/mp700113r
|
[16]
|
Dhar, S. and Bhattacharjee, P. (2021) Promising Role of Curcumin against Viral Diseases Emphasizing COVID-19 Management: A Review on the Mechanistic Insights with Reference to Host-Pathogen Interaction and Immunomodulation. Journal of Functional Foods, 82, Article ID: 104503. https://doi.org/10.1016/j.jff.2021.104503
|
[17]
|
Zahedipour, F., Hosseini, S.A., Sathyapalan, T., Majeed, M., Jamialahmadi, T., Al-Rasadi, K., Banach, M. and Sahebkar, A. (2020) Potential Effects of Curcumin in the Treatment of COVID-19 Infection. Phytotherapy Research, 34, 2911-2920. https://doi.org/10.1002/ptr.6738
|
[18]
|
Ratia, K., Saikatendu, K.S., Santarsiero, B.D., Barretto, N., Baker, S.C., Stevens, R.C. and Mesecar, A.D. (2006) Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease: Structure of a Viral Deubiquitinating Enzyme. Proceedings of the National Academy of Sciences of the United States of America, 103, 5717-5722. https://doi.org/10.1073/pnas.0510851103
|
[19]
|
Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A., Schulz, L., Widera, M., Mehdipour, A.R., Tascher, G., Geurink, P.P., Wilhelm, A., van Noort, G.J.V., Ovaa, H., Muller, S., Knobeloch, K.P., Rajalingam, K., Schulman, B.A., Cinatl, J., Hummer, G., Ciesek, S. and Dikic, I. (2020) Papain-Like Protease Regulates SARS-CoV-2 Viral Spread and Innate Immunity. Nature, 587, 657-662. https://doi.org/10.1038/s41586-020-2601-5
|
[20]
|
Razali, R., Asis, H., Budiman, C. (2021) Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms, 9, Article No. 2481. https://doi.org/10.3390/microorganisms9122481
|
[21]
|
Jin, Z.M., Du, X.Y., Xu, Y.C., Deng, Y.Q., Liu, M.Q., Zhao, Y., Zhang, B., Li, X.F., Zhang, L.K., Peng, C., Duan, Y.K., Yu, J., Wang, L., Yang, K.L., Liu, F.J., Jiang, R.D., Yang, X.L., You, T., Liu, X.C., Yang, X.N., Bai, F., Liu, H., Liu, X., Guddat, L.W., Xu, W.Q., Xiao, G.F., Qin, C.F., Shi, Z.L., Jiang, H.L., Rao, Z.H. and Yang, H.T. (2020) Structure of MPro from SARS-CoV-2 and Discovery of Its Inhibitors. Nature, 582, 289-293. https://doi.org/10.1038/s41586-020-2223-y
|
[22]
|
Qneibi, M., Hamed, O., Fares, O., Jaradat, N., Natsheh, A.R., AbuHasan, Q., Emwas, N. and Al-Kerm, R. (2019) The Inhibitory Role of Curcumin Derivatives on AMPA Receptor Subunits and Their Effect on the Gating Biophysical Properties. European Journal of Pharmaceutical Sciences, 136, Article ID: 104951. https://doi.org/10.1016/j.ejps.2019.06.005
|
[23]
|
Lowe, D.M., Corbett, P.T., Murray-Rust, P. and Glen, R.C. (2011) Chemical Name to Structure: OPSIN, an Open Source Solution. Journal of Chemical Information and Modeling, 51, 739-753. https://doi.org/10.1021/ci100384d
|
[24]
|
O’Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T. and Hutchison, G.R. (2011) Open Babel: An Open Chemical Toolbox. Journal of Cheminformatics, 3, Article No. 33. https://doi.org/10.1186/1758-2946-3-33
|
[25]
|
Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S. and Olson, A.J. (2009) AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. Journal of Computational Chemistry, 30, 2785-2791. https://doi.org/10.1002/jcc.21256
|
[26]
|
Sabbah, D.A., Hajjo, R., Bardaweel, S.K., Zhong, H.A. (2021) An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors. Current Topics in Medicinal Chemistry, 21, 442-460. https://doi.org/10.2174/1568026620666201207095117
|
[27]
|
Baez-Santos, Y.M., St John, S.E. and Mesecar, A.D. (2015) The SARS-Coronavirus Papain-Like Protease: Structure, Function and Inhibition by Designed Antiviral Compounds. Antiviral Research, 115, 21-38. https://doi.org/10.1016/j.antiviral.2014.12.015
|